Search Within

Hamza Hashmi

Formats
  1. Meeting Abstract (28)
  2. Journal Article (8)
  3. Research Letter (2)
  4. Review (2)
  5. Correspondence (1)
  6. Editorial (1)
Groups
  1. Center for Hematologic Malignancies (19)
  2. Department of Medicine (19)
  3. Hematologic Malignancies, Division of (19)
  4. Bone Marrow Transplant (18)
  5. Myeloma (18)
  6. Survivorship Research (18)

More Groups

People
  1. Sridevi Rajeeve (20)
  2. Saad Usmani (19)
  3. Heather Landau (18)
  4. Sham Mailankody (18)
  5. Alexander Lesokhin (17)
  6. Carlyn Rose Tan (17)

More People

Years
  1. 2025 (3)
  2. 2024 (39)
Publications
  1. Clinical Lymphoma, Myeloma and Leukemia (15)
  2. Blood (14)
  3. Blood Cancer Journal (3)
  4. European Journal of Haematology (2)
  5. Blood Advances (1)
  6. British Journal of Haematology (1)

More Publications

Publishers
  1. Elsevier Inc. (16)
  2. American Society of Hematology (15)
  3. John Wiley & Sons (3)
  4. Nature Publishing Group (3)
  5. Biomed Central Ltd (1)
  6. Frontiers Media S.A. (1)

More Publishers

Results (42)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Comparison of acute kidney injury in patients with relapsed or refractory multiple myeloma following CAR T-cell and bispecific antibody therapies
    Meeting Abstract

    Nishimura, N.; Mailankody, S.; Nemirovsky, D.; Derkach, A.; Costa, B. A.; Farzana, T.; Shaikh, A.; Latcha, S.; Gutgarts, V.; Jurgens, E. M.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Infectious complications during treatment with commercial CAR T-cell therapy and bispecific antibodies for relapsed/refractory multiple myeloma
    Meeting Abstract

    Jurgens, E. M.; Shekarkhand, T.; Farzana, T.; Rueda, C.; Nemirovsky, D.; Derkach, A.; Firestone, R. S.; Nishimura, N.; Miller, K.; Costa, B. A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Manufacture of anti-BCMA CAR T cell is feasible after salvage autologous or allogeneic hematopoietic stem cell transplantation
    Meeting Abstract

    Shah, G. L.; Perica, K.; Nagel, K.; Payson, E.; Hosszu, K. K.; Chung, D. J.; Landau, H. J.; Scordo, M.; Hultcrantz, M.; Korde, N.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Safety and efficacy of belantamab mafadotin in patients with relapsed/refractory multiple myeloma: A real-world experience
    Meeting Abstract

    Dileo, R.; Mewawalla, P.; Patrus, G.; Strouse, C.; Chen, E.; Shaikh, H.; Davis, J. A.; Green, K. M.; Alkharabsheh, O.; Rashid, A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Delayed neurotoxicity after CAR-T in multiple myeloma: Results from a global IMWG registry
    Meeting Abstract

    Kumar, A. D.; Atallah-Yunes, S. A.; Rajeeve, S.; Abdelhak, A.; Hashmi, H.; Corraes, A.; Htut, M.; Rodriguez-Otero, P.; Parrondo, R. D.; Chhabra, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Frailty and outcomes after bispecific T-cell engager therapy for patients with relapsed/refractory multiple myeloma
    Meeting Abstract

    Adegbite, B. O.; Tan, C. R.; Shekarkhand, T.; Firestone, R. S.; Jurgens, E. M.; Miller, K.; Lesokhin, A. M.; Shah, G. L.; Korde, N.; Rajeeve, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Treatment of relapsed/refractory multiple myeloma with ciltacabtagene autoleucel or idecabtagene vicleucel in racial minorities - A multicenter study
    Meeting Abstract

    Chang, D.; Habib, A.; Vegel, A.; Struble, E.; Shaikh, H.; Strouse, C.; Green, K. M.; Mushtaq, M. U.; Mahmoudjafari, Z.; Hashmi, H.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy
    Journal Article

    Merz, M.; Dima, D.; Hashmi, H.; Ahmed, N.; Stölzel, F.; Holderried, T. A. W.; Fenk, R.; Müller, F.; Tovar, N.; Oliver-Cáldes, A.; more...
    Blood Cancer Journal (2024)

    Fulltext@MSK | Save
  • Defining the rates of cytokine release syndrome associated with Talquetamab step-up doses
    Meeting Abstract

    Hamadeh, I.; Shekarkhand, T.; Rueda, C.; Firestone, R.; Wang, A.; Korde, N.; Hultcrantz, M.; Lesokhin, A.; Mailankody, S.; Hassoun, H.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Comprehensive genomic sequencing predicts sub-optimal response to bispecific antibodies (BsAb) and chimeric antigen receptor T cells (CAR-T) in multiple myeloma (MM)
    Meeting Abstract

    Maclachlan, K.; Shekarkhand, T.; Farzana, T.; Costa, B.; Firestone, R.; Jurgens, E.; Rajeeve, S.; Hashmi, H.; Hassoun, H.; Shah, U.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save